Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Yamo Deniz acquired 1,375 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average price of $25.40 per share, with a total value of $34,925.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at $127,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Yamo Deniz also recently made the following trade(s):

  • On Tuesday, September 5th, Yamo Deniz acquired 1,000 shares of Flexion Therapeutics stock. The stock was purchased at an average price of $24.20 per share, with a total value of $24,200.00.
  • On Friday, September 1st, Yamo Deniz acquired 3,000 shares of Flexion Therapeutics stock. The stock was purchased at an average price of $24.15 per share, with a total value of $72,450.00.

Flexion Therapeutics, Inc. (FLXN) opened at 24.12 on Monday. The company’s market cap is $769.55 million. Flexion Therapeutics, Inc. has a one year low of $15.88 and a one year high of $29.41. The stock has a 50 day moving average price of $23.25 and a 200 day moving average price of $22.01.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11). On average, equities analysts anticipate that Flexion Therapeutics, Inc. will post ($3.70) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Flexion Therapeutics, Inc. (FLXN) Insider Purchases $34,925.00 in Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/18/flexion-therapeutics-inc-flxn-insider-purchases-34925-00-in-stock.html.

FLXN has been the subject of a number of recent analyst reports. Northland Securities initiated coverage on shares of Flexion Therapeutics in a research report on Thursday, August 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Royal Bank Of Canada reiterated a “buy” rating and set a $44.00 target price on shares of Flexion Therapeutics in a report on Friday, July 7th. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, May 22nd. Finally, BMO Capital Markets reiterated a “buy” rating on shares of Flexion Therapeutics in a report on Tuesday, June 27th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Flexion Therapeutics has an average rating of “Buy” and an average price target of $31.50.

Several large investors have recently bought and sold shares of FLXN. Fiduciary Trust Co. bought a new stake in shares of Flexion Therapeutics during the second quarter worth about $101,000. IFP Advisors Inc increased its position in shares of Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after acquiring an additional 1,000 shares in the last quarter. Advisor Group Inc. increased its position in shares of Flexion Therapeutics by 205.9% during the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 3,500 shares in the last quarter. Voya Investment Management LLC increased its position in shares of Flexion Therapeutics by 25.8% during the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after acquiring an additional 2,651 shares in the last quarter. Finally, BB&T Securities LLC bought a new stake in shares of Flexion Therapeutics during the second quarter worth about $289,000. 82.75% of the stock is owned by institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.